- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Slides: 1–7 of 7
Clinically Significant Outcomes of Interest (1 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | physician global assessment | ACR Ped | parent global assessment | active joint count | erythrocyte sedimentation rate | ESR | radiographic
Results: Combining Nonbiologic DMARDs and Conventional Anti-inflammatory Drugs
Keywords: juvenile idiopathic arthritis | JIA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | D-penicillamine | hydroxychloroquine | sulfasalazine | azathioprine | methotrexate | affected joint count | global activity | radiographic
Results: Head-to-Head Comparisons of DMARDs
Keywords: anti-rheumatic | antirheumatic | biologic DMARD | D-penicillamine | disease-modifying | DMARDs | erythrocyte sedimentation rate | ESR | etanercept | health status | hydroxychloroquine | infliximab | JCA | JIA | JRA | juvenile rheumatoid arthritis | leflunomide | methotrexate | non-biologic DMARD | nonbiologic DMARD | oligoarticular | parent global assessment | pauciarticular | physician global assessment | polyarticular | radiographic progression | rheumatic | sulfasalazine | systemic onset | TNF-alpha blockers | juvenile idiopathic arthritis
Evaluating JIA Assessment Instruments (1 of 3)
Keywords: active joint count | anti-rheumatic | antirheumatic | assessment | biologic DMARD | CHAQ | CHQ | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | parent global assessment of well-being | PedsQL | PedsQL-RM | physician global assessment | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
Results From Evaluation of JIA Assessment Instruments (1 of 2)
Keywords: active joint count | AJC | anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | parent assessment of well-being | PGA | PGW | physician global assessment | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
Results From Evaluation of JIA Assessment Instruments (2 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | assessment | validity | reliability | responsiveness | active joint count | physician global assessment | parent assessment of well-being | AJC | PGA | PGW | CHAQ | CHq | PedsQL | PedsQl-RM
Conclusions About Benefits and Adverse Effects of DMARDs (1 of 2)
Keywords: active joint count | AJC | anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | parent assessment of well-being | PGA | PGW | physician global assessment | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
Your slide tray is being processed.